Qualitative or quantitative defects of sarcoglycan

Qualitative or quantitative defects of sarcoglycan (Orphanet code 207052) is a group classification encompassing a set of rare inherited muscular dystrophies known as sarcoglycanopathies. These conditions are caused by mutations in genes encoding sarcoglycan proteins (alpha, beta, gamma, or delta sarcoglycan), which are essential components of the dystrophin-associated glycoprotein complex in skeletal and cardiac muscle cell membranes. When sarcoglycans are absent, reduced in quantity (quantitative defect), or structurally abnormal (qualitative defect), the muscle fiber membrane becomes unstable and susceptible to damage during contraction, leading to progressive muscle degeneration. The sarcoglycanopathies are classified as limb-girdle muscular dystrophies (LGMD), specifically LGMD R3 (alpha-sarcoglycanopathy), LGMD R4 (beta-sarcoglycanopathy), LGMD R5 (gamma-sarcoglycanopathy), and LGMD R6 (delta-sarcoglycanopathy). Key clinical features include progressive proximal muscle weakness predominantly affecting the pelvic and shoulder girdle muscles, elevated serum creatine kinase levels, difficulty walking, climbing stairs, and rising from the floor, calf pseudohypertrophy, and in some subtypes, cardiac involvement including dilated cardiomyopathy. Onset is typically in childhood or adolescence, though severity and progression vary depending on the specific gene involved and the nature of the mutation. There is currently no cure for sarcoglycanopathies. Management is supportive and multidisciplinary, including physical therapy to maintain mobility, orthopedic interventions for contractures and scoliosis, respiratory support as needed, and cardiac monitoring particularly in beta- and delta-sarcoglycanopathies. Gene therapy approaches are under active investigation in clinical trials, particularly for alpha-sarcoglycanopathy, offering hope for future disease-modifying treatments. Genetic counseling is recommended for affected families.

Common questions about Qualitative or quantitative defects of sarcoglycan